2. Search Result
Search Result
Results for "

LMP2

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Peptides

11

Recombinant Proteins

2

Antibodies

1

Click Chemistry

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101786
    KZR-504
    5 Publications Verification

    		 Proteasome Inflammation/Immunology
    KZR-504 is a highly selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2), with IC50s of 51 nM, 4.274 μM for LMP2 and LMP7, respectively. KZR-504 is of interest for the treatment of autoimmune disease .
    KZR-504
  • HY-123052
    Ac-PAL-AMC

    		Proteasome Inflammation/Immunology
    Ac-PAL-AMC is a fluorogenic substrate specific for 20S proteasome LMP2/β1i activity .
    Ac-PAL-AMC
  • HY-114419
    Zetomipzomib
    4 Publications Verification

    KZR-616

    		 Proteasome Inflammation/Immunology
    Zetomipzomib (KZR-616), a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. Zetomipzomib has the potential for the research of multiple autoimmune diseases [2].
    Zetomipzomib
  • HY-114419A
    Zetomipzomib maleate
    4 Publications Verification

    KZR-616 maleate

    		 Proteasome Inflammation/Immunology
    Zetomipzomib (KZR-616) maleate, a first-in-class immunoproteasome inhibitor, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP2/mLMP2) subunits of the immunoproteasome. Zetomipzomib maleate has the potential for the research of multiple autoimmune diseases [2].
    Zetomipzomib maleate
  • HY-119037
    UK-101

    		Proteasome Apoptosis Cancer
    UK-101 is a potent and selective immunoproteasome β1i (LMP2) inhibitor with an IC50 value of 104 nM, displays 144- and 10-fold selectivity over β1c (IC50=15 μM) and β5 subunit (IC50=1 μM), respectivey . UK-101 induces cell apoptosis and can be used for the study of prostate cancer [2].
    UK-101
  • HY-114170
    ML604440
    3 Publications Verification

    		 Proteasome Inflammation/Immunology
    ML604440 is a specific and cell-permeable Proteasome β1i (LMP2) subunit inhibitor. ML604440 can be used in experimental colitis, EAE and autoimmune disease research. ML604440 shows synergistic effects and advantageous when combined with LMP7 inhibitor [2] .
    ML604440
  • HY-P5470
    LMP2A (426-434)

    		EBV IFNAR Inflammation/Immunology
    LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A*02 subtypes (A*02:01, A*02:03, A*02:06 and A*02:07). LMP2A (426-434) can induce a strong IFN-γ secretion response, stimulating the production of a high proportion of CD8 + IFN-γ + T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) [2].
    LMP2A (426-434)
  • HY-162754
    LMP7/LMP2-IN-1

    		Proteasome Inflammation/Immunology
    LMP7/LMP2-IN-1 (Compound 19) is the orally active inhibitor for immunoproteasome subunits LMP7 and LMP2 with IC50 of 257 and 10 nM. LMP7/LMP2-IN-1 reduces the generation of antibody, downregulates the cells in spleen germinal center B and in plasma in NP-OVA-immunized mice, and can be used in research about autoimmune diseases .
    LMP7/LMP2-IN-1
  • HY-108553
    Dihydroeponemycin

    		Proteasome Apoptosis Cancer
    Dihydroeponemycin, an analogue of the antitumor and antiangiogenic natural product eponemycin, selectively targets the 20S proteasome. Dihydroeponemycin covalently modifies a subset of catalytic proteasomal subunits, binding preferentially to the IFN-gamma-inducible subunits LMP2 and LMP7. Dihydroeponemycin-mediated proteasome inhibition induces a spindle-like cellular morphological change and apoptosis .
    Dihydroeponemycin
  • HY-112946
    LU-001i

    		Proteasome Inflammation/Immunology
    LU-001i is a highly specific proteasome β1i (LMP2) inhibitor. LU-001i alone has no significant immunomodulatory effect, but when combined with the LMP7 inhibitor (PRN1126), it can exert anti-inflammatory and immunomodulatory effects. LU-001i can be used for the study of autoimmune diseases .
    LU-001i
  • HY-113526
    AR-12463

    		Drug Derivative Endogenous Metabolite Cardiovascular Disease
    AR-12463 is a derivative of Trapidil (HY-B1016). AR-12463 inhibits the conversion of [14C]acetate to cholesterol. AR-12463 significantly reduces the elevation of total cholesterol in rabbit serum and prevents cholesterol incorporation into tissues. AR-12463 can be used to study atherosclerosis.
    AR-12463
  • HY-169480
    Lipid C2

    		Liposome Infection Cancer
    Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 +CD8 + central and CD3 +CD8 + effector memory T cells and decrease the percentage of CD3 + T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .
    Lipid C2
  • HY-101786R
    KZR-504 (Standard)

    		Reference Standards Proteasome Inflammation/Immunology
    KZR-504 (Standard) is the analytical standard of KZR-504 (HY-101786). This product is intended for research and analytical applications. KZR-504 is a highly selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2), with IC50s of 51 nM, 4.274 μM for LMP2 and LMP7, respectively. KZR-504 is of interest for the treatment of autoimmune disease .
    KZR-504 (Standard)
  • HY-182325
    DB-310

    		Proteasome Interleukin Related Neurological Disease
    DB-310 is a selective immunoproteasome LMP2 inhibitor with an IC50 value of 80.62 nM. DB-310 inhibits the production of IL-1α in microglia. DB-310 improves cognitive function in the Tg2576 transgenic mouse model of Alzheimer's disease. DB-310 can be used for research related to Alzheimer's disease .
    DB-310
  • HY-179394
    Immunoproteasome-IN-2

    		Proteasome Inflammation/Immunology
    Immunoproteasome-IN-2 is selective immunoproteasome inhibitor with IC50 = 232.3 nM for LMP7, IC50 = 9384.9 nM for β5. Immunoproteasome-IN-2 exhibits ancillary inhibitory activity against LMP2 and MECL-1 subunits. Immunoproteasome-IN-2 demonstrates anti-inflammatory efficacy in a mouse model of arthritis and shows a favorable safety profile in toxicological studies with reduced hepatotoxicity and hematotoxicity. Immunoproteasome-IN-2 has LMP7/β5 selectivity directly correlated with lower systemic toxicity. Immunoproteasome-IN-2 can be employed for research in arthritis .
    Immunoproteasome-IN-2
  • HY-RS11309
    PSMB9 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PSMB9 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMB9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PSMB9 Human Pre-designed siRNA Set A
    PSMB9 Human Pre-designed siRNA Set A
  • HY-RS17772
    Psmb9 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Psmb9 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Psmb9 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Psmb9 Mouse Pre-designed siRNA Set A
    Psmb9 Mouse Pre-designed siRNA Set A
  • HY-RS24239
    Psmb9 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Psmb9 Rat Pre-designed siRNA Set A contains three designed siRNAs for Psmb9 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Psmb9 Rat Pre-designed siRNA Set A
    Psmb9 Rat Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: